Palbociclib Isethionate

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePalbociclib Isethionate
Drug Alias NamePF-00080665-73PD-0332991-0054
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsBone metastasesMetastatic breast cancerSolid tumours +[61] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteSeagen IncWashington University School Of Medicine +[11] 
Inactive CompaniesGeorgetown University
Active IndicationsBone metastasesMetastatic breast cancerSolid tumours +[47] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungChoroid Plexus NeoplasmsMeningioma +[14] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG